Published on: 7 October 2014
Using these patient specific iPSC researchers discovered a promising way to improve the function of the defective DARS enzyme. Following testing of this novel therapeutic approach in the human stem cells and mouse models the next step will be to provide this therapy to HBSL patients with DARS mutations.